News

The randomized, double-blind, multicenter, placebo-controlled (2:1) MS-SPI trial evaluated the efficacy and safety of MD1003, 300mg/day, in patients with progressive MS who have showed progression in the two

An ODD has been applied by the company for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in

XMT-1522 is based on the company’s Fleximer immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules. Optimized for payload delivery, the conjugate uses a new

Several patients with stage IIb to IV malignant melanoma develop cutaneous metastases and samcyprone is being developed to treat these metastases. Samcyprone is a topical formulation of Diphenylcylcopropenone

Earlier, Keytruda received breakthrough therapy designation for advanced NSCLC and this sBLA seeks approval to treat these NSCLC patients whose disease has progressed on or after platinum-containing chemotherapy

In uveal melanoma, cancer cells form in the tissues of the eye and it is the most common primary intraocular malignancy in adults and comprises 5% of all

Around 24-30 patients will be enrolled in the first-in-human trial, which will be conducted at the University Hospitals of Mainz and Tuebingen in Germany. The trial will evaluate

The US Food and Drug Administration (FDA) has granted approval for Sandoz’s Glatopa, the first generic version of Teva’s Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS)

The deal aims at the development of a joint project, based on new findings by professor Aaron Ciechanover, Dr Gila Maor and professor Ofer Binah, that can potentially